Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Kidney Disease, Chronic, Diabetes, Dialy...
Phase PHASE4
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Semaglutide Pen — Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.

Primary Outcomes

  • Adherence of Study Intervention (26 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-11-27
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Unity Health Toronto
Principal Investigators:
  • Dr. Ron Wald, MD (PRINCIPAL_INVESTIGATOR) - Unity Health Toronto
Contact Information
Study Contact:
Ron Wald, MD
(416) 867-3703
ron.wald@unityhealth.to
Kevin Yau, MD
Kevin.Yau@uhn.ca
Ron Wald, MD
(416) 867-3703
ron.wald@unityhealth.to
Unity Health Toronto
Interventions
  • Drug: Semaglutide Pen — Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.
Study Locations (2 sites)
Unity Health Toronto, Toronto, Ontario M5B1W8 Canada
Unity Health Toronto, Toronto, Ontario M5B1W8 Canada
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days 3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin. 4. Ability to provided informed consent or through their substitute decision maker Exclusion Criteria: 1. Type 1 DM 2. Use of a GLP-1-RA within 30 days prior to screening 3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening) 4. Confirmed pregnancy, women of childbearing potential 5. Known hypersensitivity to GLP-1-RA 6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months 7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA
Conditions Diabete Type 2
Phase NA
Enrollment 140
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this Hybrid Type 2 effectiveness-implementation pilot randomized controlled trial is to assess the feasibility and preliminary effectiveness of a community-based wellness coaching intervention (the intervention) to prevent type 2 diabetes (T2D) among South Asian (SA) and Black African and Caribbean (BAC) communities in the Peel region of Ontario, Canada. The study evaluates the impact of the intervention on reducing diabetes risk and related intermediate outcomes, including biomarkers, anthropometric measures, well-being, knowledge, health behaviours, and family-level outcomes in the study participants. Study's SA and BAC participants will consist of a primary adult family caregiver aged 18 years or older, who does not have T2D and is not taking pharmacological treatment for blood glucose reduction, and who has children aged 25 or under living in the same household. If the Family caregiver has youth children aged 14 to 25 years residing in the same household, who want to participate in the study, they are welcome to join it but not mandatory. The study aims to generate preliminary evidence on both the implementation and effectiveness of the intervention over a six-month per person period. The overall duration of the study (implementation, effectiveness monitoring an evaluation) will be up to 16 months, from the the start of recruitment in May 2026 to the September 2027, where the intervention delivery for the last participant enrolled in the study will expected to be completed. Family caregiver participants of each ethno-cultural group (SA and BAC) will be randomly assigned to either the intervention or control arm. During the first six months, participants in the intervention arm will receive biweekly health and wellness coaching delivered by trained community-based coaches, optional group coaching sessions with other participants, weekly motivational messages, and an educational T2D prevention booklet. Participants in the control arm will receive only the educational T2D prevention booklet. Implementation and effectiveness outcomes will be assessed using a mixed-methods approach, integrating qualitative and quantitative data collected at baseline and at the 6-month post-randomization time point. This approach is intended to generate comprehensive, preliminary evidence on both the implementation and effectiveness components of the health and wellness intervention. Quantitative and mixed-methods analyses will be conducted to provide an integrated understanding of the implementation and effectiveness outcomes studied. Findings from this pilot trial will inform the design of larger, definitive studies to better assess impact and guide future escalation and/or adaptation. Results will be disseminated in multiple formats and tailored to diverse audiences, including community partners, local communities, social media, referral pathways, academics, researchers, and decision-makers.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Family Dyad Health and Wellness Coaching Session — Biweekly health and wellness coaching sessions (in-person or virtual) for type 2 diabetes, provided by trained community-based coaches. The maximum session length will be 30 minutes, with no mandatory minimum. Coaches will also share a short weekly motivational message, delivered to participants' phones or emails, depending on preferences. The intervention group participants may join an optional monthly group-based health and wellness coaching session with other program participants. Group sessions will be approximately 2 hours in length.
  • Behavioral: Educational Material — A printed or digital educational booklet on type 2 diabetes (T2D) prevention. The booklet contains information related to the causes and signs of T2D, diet and physical activity engagement activities, mental well-being enhancement and stress management, strategies to set up positive lifestyles and behavioural change, along with a list of local health and social support services that may be used to further promote overall well-being and support T2D risk reduction.

Primary Outcomes

  • Implementation Outcome: Intervention Acceptability (Six months post-randomization.)
  • Implementation Outcome: Intervention Appropriateness (Six months post-randomization.)
  • Implementation Outcome: Intervention Reach (Baseline.)
  • Implementation Outcome: Intervention Adoption (Uptake) (Six months post-randomization.)
  • Implementation Outcome: Intervention Availability (Six months post-randomization.)
  • Implementation Outcome: Intervention Fidelity (Six months post-randomization.)
  • Effectiveness Outcome: T2D Risk (Baseline and six months post-randomization.)
  • Effectiveness Outcome: Overall Quality of Life (Baseline and six months post-randomization.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-20
Completion: 2027-09-30
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: true
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Trillium Health Partners
Collaborators: Sun Life Financial Movement Disorders Research and Rehabilitation Centre
Principal Investigators:
  • Ian Zenlea, MD, MPH (PRINCIPAL_INVESTIGATOR) - Institute for Better Health, Trillium Health Partners, Mississauga.
Contact Information
Study Contact:
Cilia Mejia-Lancheros (Study Research Lead), RN, MPH, Msc. GHP, PhD
437 216 6209
Cilia.Mejia-Lancheros@thp.ca
Hamna Khan, MPP
437-231-6951
hamna.khan@thp.ca
Hamna Khan, MPP
437-231-6951
hamna.khan@thp.ca
Wellfort Community Health Services
Interventions
  • Behavioral: Family Dyad Health and Wellness Coaching Session — Biweekly health and wellness coaching sessions (in-person or virtual) for type 2 diabetes, provided by trained community-based coaches. The maximum session length will be 30 minutes, with no mandatory minimum. Coaches will also share a short weekly motivational message, delivered to participants' phones or emails, depending on preferences. The intervention group participants may join an optional monthly group-based health and wellness coaching session with other program participants. Group sessions will be approximately 2 hours in length.
  • Behavioral: Educational Material — A printed or digital educational booklet on type 2 diabetes (T2D) prevention. The booklet contains information related to the causes and signs of T2D, diet and physical activity engagement activities, mental well-being enhancement and stress management, strategies to set up positive lifestyles and behavioural change, along with a list of local health and social support services that may be used to further promote overall well-being and support T2D risk reduction.
Study Locations (2 sites)
Wellfort Community Health Services, Brampton, Ontario L6T 3J1 Canada
Punjabi Community Health Services (PCHS), Brampton, Ontario L6T 3T6 Canada
Eligibility Criteria
Inclusion Criteria: Study participants will consist of a self-identified primary family caregiver aged 18 years or older with children under 25 year of age living in the same household. Optional youth family member aged 14 to 25 years at the time of study entry are welcome but not mandatory. The primary family caregiver will serve as the primary (index) research participant for the study and should have the following inclusion criteria: 1. Self-identifies as either South Asian or Black, African and Caribbean. 2. Lives in the Peel Region (Mississauga, Brampton or Caledon), Ontario, Canada. 3. Be 18 years or older and have children aged 25 years or under in the same household. AND 4. Have no medical diagnosis (self-reported) of diabetes. 5. Have no medical diagnosis (self-reported) of prediabetes that requires any medical or pharmacological treatment. Have a blood-based sugar lower than or equal to 6.5 measured through the hemoglobin A1c test using a finger prick at the pre-enrollment assessment visit. AND 6. The family caregiver and optional youth (when participating) must be proficient in English (reading, writing, and speaking), as English will be the primary language used for the participation eligibility, implementation, delivery, and evaluation of the intervention. Exclusion Criteria for family dyad: 1. Do not meet all the criteria above. 2. A medical condition or health professional has advised them not to engage in physical activity of any type, or they are following a specific diet. 3. Cannot give informed consent to participate voluntarily in the intervention and study.

The Sunnybrook Type 2 Diabetes Study

NCT04455867
Recruiting
Conditions Type 2 Diabetes, PreDiabetes
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The Sunnybrook Type 2 Diabetes Study (S2DS) is a prospective observational study of people with prediabetes or Type 2 Diabetes Mellitus (T2DM), that aims to understand the aetiologies, manifestations, and clinical consequences of mood and cognitive complications. The study recruits from the services at Sunnybrook Health Sciences Centre and from the neighbouring University Health Network Toronto Rehabilitation Institute Cardiac Rehabilitation Program.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: Diabetes Exercise and Healthy Lifestyle Program — The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.
  • Other: Outpatient care — Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education

Primary Outcomes

  • Depressive episode (6 Months)
  • Neuropsychological function (6 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-12-21
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunnybrook Health Sciences Centre
Collaborators: University Health Network, Toronto, University of Toronto
Principal Investigators:
  • Walter Swardfager, PhD (PRINCIPAL_INVESTIGATOR) - Sunnybrook Research Institute
Contact Information
Study Contact:
Walter Swardfager, PhD
416-480-6100
w.swardfager@utoronto.ca
Chelsi Major-Orfao, MEd
416-480-6100
chelsi.major-orfao@sri.utoronto.ca
Walter Swardfager, PhD
416-480-6100
w.swardfager@utoronto.ca
Sunnybrook Research Institute
Interventions
  • Behavioral: Diabetes Exercise and Healthy Lifestyle Program — The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.
  • Other: Outpatient care — Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education
Study Locations (1 sites)
Sunnybrook Research Institute, Toronto, Ontario M4N 3M5 Canada
Eligibility Criteria
Inclusion Criteria: * Have at least one of the following: high HbA1c, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), but not yet diagnosed with Type 2 diabetes or have a diagnosis of Type 2 diabetes. * Be able to communicate in English * Be 18 years of age or older Exclusion Criteria: * Pregnancy * Inability to give informed consent * Current cancer diagnosis * Have a prior diagnosis of bipolar disorder or schizophrenia. * Have a prior diagnosis of a neurological and/or neurodegenerative disorder. * Have a current substance use disorder or a previous substance use disorder diagnosed within the last 5 years (excluding nicotine) * Poor score on the Mini Mental State Examination (MMSE) Exclusion criteria (Brain Imaging Sub-Study): * Contraindications to SHSC's MRI safety protocol. * Participants that do not meet the inclusion/exclusion criteria of the main study. Exclusion criteria for (Brain Imaging Sub-Study - CVR procedure): * Use of medical equipment that would interfere with the placement of the CVR mask. * Significant pulmonary disease (e.g. asthma, pulmonary fibrosis, emphysema, chronic obstructive pulmonary disease, pulmonary vascular disease, pleural disorders, pneumonia) * Participants that do not meet the criteria for the MRI sub-study. Exclusion criteria (Sleep Quality and Apnea Sub-Study): * Participants that have a medical device that would interfere with placement of portable sleep monitor equipment i.e. Participant requires O2 therapy and uses nasal prongs * Participants that have a condition that may compromise accuracy of the HSAT results i.e. moderate-severe pulmonary disease or congestive heart failure * Participants that do not meet the inclusion/exclusion criteria of the main study
Conditions Diabetes, Diabetes Care, Diabetes Type 1...
Phase Not Applicable
Enrollment 12000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational pre-post study is to evaluate a remote-patient-monitoring-system (RPM-system) integrated within an electronic health record (EHR) system in a real world cohort of approximately 12.000 people with diabetes in an outpatient care setting. The main question it aims to answer is: Whether glycemic outcomes following integration of the RPM system into the EHR over a two-year period are non-inferior compared with outcomes observed prior to an ambulatory care restructuring (including a prototype of the RPM-system) in October 2024. Participants are included in the RPM-system as part of their regular medical care for diabetes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Remote-Patient-Monitoring (RPM) — The RPM-system "Steno Detektor" integrated within the EHR-system

Primary Outcomes

  • Children: Composite Continuous-Glucose-Monitoring (CGM) endpoint consisting of Time-Above-Range (TAR) and Time-Below-Range (TBR) (From PRE-period (defined as 1. July 2023 to 30. June 2024) to POST-period (defined as 1. July 2027 - 30. June 2028).)
  • Adults with Type 1 diabetes: Composite Continuous-Glucose-Monitoring (CGM) endpoint consisting of Time-Above-Range (TAR) and Time-Below-Range (TBR) (From PRE-period (defined as 1. July 2023 to 30. June 2024) to POST-period (defined as 1. July 2027 - 30. June 2028).)
  • Adults with Type 2-diabetes: HbA1c (mmol/L) (From PRE-period (defined as 1. July 2023 to 30. June 2024) to POST-period (defined as 1. July 2027 - 30. June 2028).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-10
Completion: 2028-07
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 12000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Steno Diabetes Center Copenhagen
Contact Information
Study Contact:
Jonatan I. Bagger, MD, Ph.d., Chief Physician
+45 28341036
jonatan.ising.bagger@regionh.dk
Julie E. Stenvang, MD, Ph.d.-student
+45 51429941
julie.christine.egelund.stenvang.01@regionh.dk
Jonatan I. Bagger, MD, Ph.d., Chief Physician
+45 28341036
jonatan.ising.bagger@regionh.dk
Steno Diabetes Center Copenhagen
Interventions
  • Other: Remote-Patient-Monitoring (RPM) — The RPM-system "Steno Detektor" integrated within the EHR-system
Study Locations (1 sites)
Steno Diabetes Center Copenhagen, Herlev, 2730 Denmark
Eligibility Criteria
Inclusion Criteria: * All people with active clinical care at SDCC during each period and thereby included in the RPM. Exclusion Criteria: * All people without active clinical care at SDCC during each period.
Conditions Diabetic Foot Ulcer, Diabetes Mellitus, ...
Phase PHASE1
Enrollment 28
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both supplemented with platelet rich plasma (PRP) to treat chronic diabetic foot ulcers. It will increase the pragmatic potential of both types of cells as PRP is rich in survival and chemotactic factors. Moreover, the autologous nature of the proposed study will ensure safety of its use in diabetic patients and will unveil the more effective therapeutic option for treatment of foot ulcer wounds.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Control; Standard-of-care management — Patients will undergo conventional wound care management.
  • Biological: Only PRP injection — Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.
  • Biological: PRP + SVF injection — Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
  • Biological: PRP + ASCs injection — Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.

Primary Outcomes

  • Interview and visual inspection of ulcers recovery rate (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2020-11-20
Completion: 2025-12
Eligibility
Age: 20 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 28 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of the Punjab
Collaborators: Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Higher Education Commission (Pakistan), Jinnah Burn and Reconstructive Surgery Centre, Lahore
Principal Investigators:
  • Azra Mehmood, PhD (PRINCIPAL_INVESTIGATOR) - Center of Excellence in Molecular Biology (CEMB, University of the Punjab, Lahore
  • Sheikh Riazuddin, PhD (STUDY_DIRECTOR) - Jinnah Burn and Reconstructive Surgery Center (JB&RSC), Lahore
Contact Information
Study Contact:
Azra Mehmood, PhD
+92-333-4107008
azra_mehmood@hotmail.com
Amna Arif, M.Phil.
+92-333-4161068
amnaarif.qureshi@gmail.com
Dr. Moazzam Nazeer Tarar, Plastic Surgeon MBBS/ FRCS
+92-300-8423139
mntarar@gmail.com
Stem Cell Laboratory, Jinnah Burn and Reconstructive Surgery Center (JB&RSC)
Interventions
  • Other: Control; Standard-of-care management — Patients will undergo conventional wound care management.
  • Biological: Only PRP injection — Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.
  • Biological: PRP + SVF injection — Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
  • Biological: PRP + ASCs injection — Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
Study Locations (1 sites)
Stem Cell Laboratory, Jinnah Burn and Reconstructive Surgery Center (JB&RSC), Lahore, Punjab Province 54550 Pakistan
Eligibility Criteria
Inclusion Criteria: * Type 1 or Type 2 Diabetes Mellitus * Age 20-60 years (Male/Female) * Body mass index 20-30 kg/m2 * Suitable for liposuction * Condition or Disease: Diabetic Neuropathy * Wound Type: Chronic foot ulcer * Approx. wound area: 2 cm2 - 8 cm2 * Wound Condition should be of Wagner's grade I (Limited to soft tissue) * Duration of wound persistence: 6-24 Weeks * Transcutaneous oxygen pressure \> 30 mmHg, and an ankle brachial pressure index \> 0.5. * Already following an adequate off-loading method * Provided signed informed consent Exclusion Criteria: * Uncontrolled hyperglycemia (HbAlc \> 9%) * Presence of severe clinical sign of infection * Inability to tolerate off-loading, and poor prognosis diseases including malignant tumors. * Serious chronic disease i.e hepatic, heart, renal, pulmonary diseases * Patients with critical limb ischemia and osteomylitis * Withdrawal of informed consent
Conditions Diabete Type 2
Phase PHASE1, PHASE2
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase Ib/IIa, single ascending dose study of the safety, tolerability and preliminary efficacy of sublingual (SL) Liraglutide in patients with type 2 diabetes mellitus (T2DM).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Liraglutide — Sublingual or subcutaneous liraglutide
  • Drug: Placebo — Sublingual placebo

Primary Outcomes

  • Incidence, nature and severity of adverse events (Through study completion, an average of 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-04-25
Completion: 2026-03
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Biolingus
Collaborators: Chinese University of Hong Kong
Principal Investigators:
  • Elaine YK Chow (PRINCIPAL_INVESTIGATOR) - Chinese University of Hong Kong
  • Juliana CN Chan (PRINCIPAL_INVESTIGATOR) - Chinese University of Hong Kong
Contact Information
Study Contact:
Elaine YK Chow
+852 35051642
e.chow@cuhk.edu.hk
Elaine Chow, MD
Clinical Trials Unit, Chinese University of Hong Kong
Interventions
  • Drug: Liraglutide — Sublingual or subcutaneous liraglutide
  • Drug: Placebo — Sublingual placebo
Study Locations (1 sites)
Clinical Trials Unit, Chinese University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: 1. Males and females aged 18-65 years (inclusive) 2. Body mass index (BMI) 18-35 kg/m2, inclusive 3. Normal blood pressure or well managed hypertension (systolic blood pressure \<160mmHg, diastolic blood pressure \<100 mmHg) 4. Confirmed diagnosis of T2DM (by repeated laboratory findings) for at least 1 year. 5. Subjects under glycemic control on a stable dose of metformin (within the standard of care dose range up to 2 g daily) for at least 2 months prior to enrolment or those who manage their condition only by diet/exercise. 6. For subjects on a stable dose of concomitant metformin for at least 2 months prior to enrolment, the subject's dose of metformin will be required to remain constant until at least the completion of MMTT on the final dosing day. Subjects whose concomitant glucose lowering medication changes during the dosing phase of the study will be discontinued and may be replaced. 7. For subjects not in receipt of concomitant metformin for at least 2 months prior to enrolment, and who manage their condition only by diet/exercise, documentation of stable glycemic control under current condition management for at least 2 months prior to enrolment, as confirmed by HbA1c. For subjects who meet this criterion, no change in disease management is permitted until at least the completion of MMTT on the final dosing day. Any subject who requires a change in disease management, including initiation of any diabetes medication during the study, will be discontinued from the study and may be replaced. 8. Fasting plasma glucose ≥5.6 mmol/L at screening 9. HbA1c ≥6.5% and ≤9.0% at screening 10. Vital signs after 10 minutes resting supine: 1. 90 mmHg \<systolic blood pressure \<160 mmHg 2. 40 mmHg \<diastolic blood pressure \<100 mmHg 3. 40 bpm \<heart rate \<100 bpm Duplicate assessments will be performed and the average of the two assessments of blood pressure will be used. 11. Standard 12-lead ECG parameter results at screening, after 10 minutes resting in supine position, within 120 ms \<PR \<220 ms, QRS \<120 ms, QTcF ≤450 ms (males), QTcF ≤470 ms (females). 12. No history of significant cardiovascular disease over the preceding 3 years or any other major disease other than T2DM and well managed hypertension, unless permitted at the discretion of the PI. 13. Negative test for selected drugs of abuse at screening (does not include alcohol) and at admission (testing at admission does include alcohol breath test). A positive result may be verified by re-testing (up to one false positive result permitted) and may be followed up at the discretion of the PI. 14. Females must be non-pregnant and non-lactating, and either surgically sterile for a minimum of 6 months (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy), or use highly effective contraceptive method (oral contraceptives pills, long-acting implantable hormones, injectable hormones, a vaginal ring or an intrauterine device \[IUD\]) from screening until study completion, or be post-menopausal for ≥12 months. Post-menopausal status will be confirmed through testing of follicle-stimulating hormone (FSH) levels (≥ 40 IU/mL) at screening for amenorrheic female subjects. Females who are abstinent from heterosexual intercourse will also be eligible. 15. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and admission and be willing to have additional pregnancy tests as required throughout the study. 16. Males must be surgically sterile (\>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a WOCBP, the subject and his partner must be surgically sterile (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from screening until study completion. Acceptable methods of contraception include the use of condoms and the use of an effective contraceptive for the female partner (WOCBP), as per Inclusion Criterion #14. Male subjects whose female partner is post-menopausal, and subjects who are abstinent from heterosexual intercourse will also be eligible. Male subjects must agree to refrain from donating sperm from screening until study completion. Exclusion Criteria: 1. Pregnant or lactating, or intending to become pregnant within 30 days after last dose of study drug. 2. Participation in a clinical trial within 30 days before enrolment; use of any experimental oral therapy within 30 days or 5 half-lives prior to enrolment, whichever is greater; or use of any biologic therapy within 12 weeks or 5 half-lives prior to enrolment, whichever is greater. Subjects who have received an experimental therapy that has no half-life, such as a vaccine, should have completed that therapy at least 30 days prior to enrolment. 3. Any vaccine 2 weeks prior to first study drug administration until 2 weeks after the last dose, with the exception of current seasonal influenza vaccination. 4. Use of any weight loss agent within the preceding 4 weeks. 5. Surgery or hospitalization during the 4 weeks prior to screening. 6. Planned procedure or surgery during the study. 7. Blood transfusion within 8 weeks prior to screening. 8. Donation or loss of blood (excluding the volume of blood that will be drawn during screening procedures) as follows: ≥ 300 mL of blood within 30 days prior to study drug administration. 9. Poor peripheral venous access. 10. Alcohol and/or substance abuse or dependence within the past 2 years. 11. Within the last 2 years, unstable or clinically significant cardiovascular disease (e.g. myocardial infarction, angina pectoris, New York Heart Association Class II or more cardiac failure). 12. History of pancreatitis 13. History or presence of an abnormal ECG that is clinically significant in the PI's opinion and/or evidence of prior myocardial infarction within 2 years before screening. 14. History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease, coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g. hypokalemia, hypomagnesemia, hypocalcaemia), or family history of sudden unexplained death or long QT syndrome. 15. Impaired hepatic function as indicated by screening aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2 x or total bilirubin ≥ 1.5 x the upper limit of normal (ULN), which remains above these limits if retested due to a slightly elevated initial result or abnormalities in synthetic function tests that are judged by the PI to be clinically significant. 16. Unstable hypo- or hyperthyroidism. 17. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome Type 2. 18. Current or history of bulimia or anorexia nervosa. 19. History of severe allergy (requiring hospital care), severe reaction to any drug, or any known or suspected allergies or sensitivities to the study drug constituents. 20. Diagnosis with Type 1 Diabetes Mellitus (T1DM) or any previous episodes of diabetic ketoacidosis. 21. History of or ongoing inflammatory bowel disease or diabetic gastroparesis. 22. Severe hypoglycaemia resulting in seizure/unconsciousness/coma/hospitalization in the last 3 months before screening. 23. Persistent hyperglycaemia not controlled by metformin/diet/exercise. 24. Proliferative retinopathy, nephropathy or renal impairment (\<60 mL/min as calculated by the CKD-EPI equation) if deemed clinically significant by the PI. 25. Any other serious medical condition, or abnormality in clinical laboratory tests, that would preclude the subject's safe participation in and completion of the study or increase the expected risk of exposure to the investigational product (IP) or would be expected to interfere with the planned evaluations, in the judgment of the PI. 26. Use of diabetes medic
Conditions Allergic Diseases, Asthma, Mast Cell Dis...
Phase Not Applicable
Enrollment 3200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to build up a clinico-biological bank of samples from patients suspected of or suffering from allergic diseases (including asthma) or mast cell diseases in order to support future research in the field of allergic diseases. The biobank will help to identify new prognostic, diagnostic and/or predictive biomarkers.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Biobanking for Biomarkers In Respiratory Disease, Allergic diseases and/or mast cell disorders (15 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-28
Completion: 2038-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Toulouse
Principal Investigators:
  • Laurent GUILLEMINAULT, MD (PRINCIPAL_INVESTIGATOR) - University Hospital, Toulouse
Contact Information
Study Contact:
Laurent GUILLEMINAULT, MD
05 67 77 17 51
guilleminault.l@chu-toulouse.fr
Laurent GUILLEMINAULT, MD
05 67 77 17 51
guilleminault@chu-toulouse.fr
Laurent GUILLEMINAULT
Cristina LIVIDEANU, MD
Laurent GUILLEMINAULT
Interventions
N/A
Study Locations (1 sites)
Laurent GUILLEMINAULT, Toulouse, 31059 France
Eligibility Criteria
Inclusion Criteria: * patients with a positive prick test or specific IgE regardless of the allergen * patients suspected of allergic pathology defined by the need to carry out a prick test or specific IgE or a food or drug reintroduction test as part of the treatment * patients with systemic or cutaneous mastocytosis according to the international classification8 * patients with mast cell activation syndrome according to the international classification8 * patients with familial hyper-alpha tryptasemia on the presence of variation in the number of copies of the alpha allele of the TPSAB1 gene * patients with asthma of any severity * people affiliated or beneficiaries of a social security scheme * patients able to receive and understand the information on the study and their participation and having freely consented to it in writing before any collection of samples or data necessary for the research (no restriction of rights by the judicial authorities and mastery of the French language). Exclusion Criteria: * patients under legal protection, guardianship or curatorship * pregnant or breastfeeding women
Conditions Suspected Asthma
Phase NA
Enrollment 500
Locations 25 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This is a multi-center study to explore the positive predictive value of bronchodilation test with portable oscillometry compared to either BDT or BPT with spirometry in asthma diagnosis and to compare it with bronchodilation with spirometry (the current gold standard). In the study, the target patients' profile is the suspected asthma patient with asthmatic symptoms (wheezing, shortness of breath, chest tightness, and/or cough) and aim to enroll 500 participants from 25 sites across different regions in China.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Pulmonary function Test intervention — enrollment 500 suspect asthma patients

Primary Outcomes

  • To explore the diagnostic value of portable oscillometry in suspected asthma patients (day 0~7)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-10
Completion: 2027-06-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Principal Investigators:
  • KeWu Huang, Doctor (PRINCIPAL_INVESTIGATOR) - Beijing Chao-Yang Hospital, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China
  • Min Zhang, Doctor (PRINCIPAL_INVESTIGATOR) - No. 85/86, Wujin Road, Hongkou District, Shanghai
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Device: Pulmonary function Test intervention — enrollment 500 suspect asthma patients
Study Locations (25 sites)
Research Site, Beijing, 100000 China
Research Site, Cangzhou, 061000 China
Research Site, Changsha, 410008 China
Research Site, Changsha, 430033 China
Research Site, Chengdu, 610041 China
Research Site, Chongqing, 400016 China
Research Site, Guangzhou, 510000 China
Research Site, Guangzhou, 510000 China
Research Site, Guangzhou, 510120 China
Research Site, Guangzhou, 510630 China
Eligibility Criteria
Inclusion Criteria: Participants must meet all the following criteria and sign an informed consent form (ICF) to be eligible for the study. 1. Patient must be aged 18-75 years old at the time of enrollment. 2. Presented with asthmatic symptoms such as wheezing, shortness of breath, chest tightness and cough ≥2 months prior to enrollment (Day 0), with/without an established asthma diagnosis. Exclusion Criteria: Patients are excluded from the study if any of the following criteria apply: Medical Conditions 1. Respiratory infections within 3 months prior to enrollment (Day 0), including but not limited to: acute bacterial/viral pneumonia, acute bronchitis, Influenza, COVID-19 or acute exacerbation of chronic bronchitis. 2. Current smoker; or cessation from smoking less than 6 months; or cessation smoking for more than 6 months but smoked more than 10 packs/year. 3. History of other chronic respiratory diseases other than asthma, including but not limited to tuberculosis, significant bronchiectasis, established interstitial lung disease, and lung cancer. 4. History of serious comorbidities, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could: 1. Affect the safety of the patient throughout the study, 2. Confound the study results or impact the scientific validity of the data outcome, 3. Impede the patient's ability to complete the entire duration of study. 5. Positive urine pregnancy test, or breastfeeding women, or any women who are planning to become pregnant (current and within 3 months). Prior/Concomitant Therapy 6. ICS-based medication (including ICS, ICS/LABA, ICS/LABA/LAMA) use within 3 months prior to enrollment (Day 0). ICS=inhaled corticosteroids; LABA=long-acting β2 agonists; LAMA=long-acting muscarinic antagonists. Other Exclusions 7. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 8. Current participation in another interventional clinical trial.
Conditions Asthma (Diagnosis)
Phase Not Applicable
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

Background and study aims: The purpose of this research registry is to understand how asthma varies from person to person and monitor changes that may occur over time. The effects that asthma has on the body will be assessed, by looking at different causes/triggers of flare-ups/exacerbations, asthma symptoms, and how inflammation of the airways may affect respiratory health over time. The information obtained from this study will allow hVIVO to better understand respiratory disease progression and outcomes in asthma patients. Who can participate: Male or Female patients aged ≥ 18 years who are attending the hVIVO respiratory site clinics and have a clinical diagnosis of asthma. What does the study involve: The study will consist of a baseline clinic visit to confirm suitability and assess participants' asthma followed by approximately 5 annual clinic visits and follow-up phone calls, as necessary. Intermediate home self-assessments will also be scheduled for halfway between each annual clinic visit. Upon experiencing cold-like symptoms, participants will be asked to complete a at home self-nasal and throat swab as well as symptom, medication, and lung function home diary cards. What are the possible benefits and risks of participating: Taking part will not improve participants' health, although participants might benefit from a general health check at Screening as well as additional health checks and assessments of participants' inhaler technique during the conduct of the study. There may be unexpected and unforeseen risks related to the study procedures. When attending for clinic visits, assessment will be performed by appropriately trained and qualified staff. Participants will be monitored for any procedure related symptoms such as, pain or bruising at the site where blood is drawn. Discomfort, sneezing, watery eyes, irritated nose, or nose bleeding during nasal sample collection. Light-headedness, dizziness, fatigue, coughing, shortness of breath, headaches, chest discomfort, throat irritation and itching during lung function testing. Skin irritation and allergic reactions from skin prick testing. Should participants experience any of these symptoms, trained staff will be on hand to provide the appropriate medical treatment. The Methacholine bronchial challenge test is also likely to cause asthma symptoms such as wheezing, shortness of breath, and chest tightness. In rare cases, the test can cause severe bronchospasm. After the test or if the bronchospasm is severe, the technician will give the participant medication to inhale that will open the airways. If the participant experiences any asthma exacerbation as a result of the methacholine test, the exacerbation management guidelines will be used to assess the participant and guide treatment. Only participants that are not contraindicated for a methacholine test will have this performed. For the at home assessments, participants will receive proper training on how to perform…

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Exacerbation history (number and severity) (Baseline, Year 1, 2, 3, 4, 5)
  • Spirometry - change in Forced Expiratory Volume in 1 second (FEV1) (Litres [L]) (Change from baseline FEV1 at Year 1, 2, 3, 4, 5)
  • Spirometry - change in Forced Vital Capacity (FVC) (L) (Change from baseline FVC at Year 1, 2, 3, 4, 5)
  • Spirometry - change in Peak Expiratory Flow (PEF) (Litre/second [L/s]) (Change from baseline PEF at Year 1, 2, 3, 4, 5)
  • Spirometry - change in Forced Expiratory Flow at 25-75% of the forced vital capacity (FEF25-75%) (L/s) (Change from baseline FEF25-75% at Year 1, 2, 3, 4, 5)
  • Post-bronchodilator spirometry - FEV1 (L) (Optionally Year 1,2,3,4,5)
  • Post-bronchodilator spirometry - FVC (L) (Time Frame: Optionally Year 1,2,3,4,5)
  • Post-bronchodilator spirometry - PEF (L/s) (Optionally Year 1,2,3,4,5)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-08
Completion: 2050-08-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hvivo
Collaborators: King's College London
Principal Investigators:
  • Alexandre Lima, MD-PhD (PRINCIPAL_INVESTIGATOR) - Hvivo
Contact Information
Study Contact:
Alex Mann
+44 (0)207 756 1300
projectadmin@hvivo.com
Alexandre Lima, MD-PhD
+44 (0)207 756 1300
projectadmin@hvivo.com
Alexandre Lima, MD-PhD
+44 (0)207 756 1300
projectadmin@hvivo.com
hVIVO Services Limited, 40 Bank Street
Interventions
N/A
Study Locations (1 sites)
hVIVO Services Limited, 40 Bank Street, London, E14 5NR United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Male or Female patients aged ≥ 18 years and older who have signed an Informed Consent form. 2. All patients who attend the hVIVO respiratory site clinics who have a clinical diagnosis of asthma/any of the following: * Positive response to methacholine challenge test (AHR), or * Positive response to a bronchodilator responsiveness test, or * Peak Flow variability (i.e. highest - lowest PEF over the day/mean value of the two, × 100) \> 20%, or * Documented response (defined as ΔFEV1 ≥ 12% and ≥ 200 mL) after a cycle (e.g., 4 weeks) of regular maintenance anti-asthma treatment, or * physician diagnosis of current asthma. 3. In the PI/investigator(s) opinion, will be able to follow the study requirements. Exclusion Criteria: 1. Asthma patients who are not attending hVIVO respiratory site clinics. 2. Patients whose primary respiratory diagnosis (i.e. the condition causing most of their respiratory symptoms) is not asthma (however, a co-diagnosis of another respiratory disease such as COPD, bronchiectasis or interstitial lung disease together with asthma will be accepted) 3. Females who: 1. Are breastfeeding, or 2. Have a positive pregnancy test at any point during screening 4. Patients who, in the opinion of the physician, are unlikely to complete the 5 years of follow-up, e.g. poor literacy, substance abuse, life threatening comorbidities. 5. Contraindications for lung function testing, e.g., hemoptysis of unknown origin, history of pulmonary hypertension, previous pneumothorax, unstable cardiovascular status (severe heart failure, or ischemic heart disease), aneurysms (thoracic, abdominal or cerebral), recent eye surgery (e.g., cataract), recent thoracic or abdominal surgery. 6. Patients with lifetime history of anaphylaxis and/or a lifetime history of severe allergic reaction
Conditions Asthma (Diagnosis)
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to compare the effects of virtual reality-based aerobic exercise and treadmill-based aerobic exercise on functional capacity, pulmonary function, and clinical outcomes in children with asthma. Participants aged 10-17 years with physician-diagnosed asthma will be randomly assigned to either a virtual reality-based exercise group or a treadmill exercise group. Both groups will undergo supervised exercise training sessions twice a week for 8 weeks. Primary outcome will be the 6-Minute Walk Test. Secondary outcomes include pulmonary function, respiratory muscle strength, asthma control, quality of life, and exercise adherence.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Virtual Reality-Based Aerobic Exercise — Participants will perform supervised moderate-intensity aerobic exercise using a Meta Quest 3S virtual reality headset and game-based activities. Each session will include a 5-minute warm-up period, 30 minutes of aerobic exercise, and a 5-minute cool-down period. Sessions will be conducted twice weekly for 8 week
  • Behavioral: Treadmill-Based Aerobic Exercise — Participants will perform supervised moderate-intensity treadmill-based aerobic exercise. Each session will include a 5-minute warm-up period, 30 minutes of aerobic exercise, and a 5-minute cool-down period. Sessions will be conducted twice weekly for 8 weeks.

Primary Outcomes

  • Functional Capacity: 6-Minute Walk Test Distance (Baseline and Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-25
Completion: 2027-05-10
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bezmialem Vakif University
Contact Information
Study Contact:
Ayşe Sena Manzak Dursun, PT, PhD
+905356735150
amanzak@bezmialem.edu.tr
Fuat Gokdemir, PT, MSc
+90 554 372 70 84
fuat.gokdemir@bezmialem.edu.tr
Bezmialem Vakif University
Interventions
  • Device: Virtual Reality-Based Aerobic Exercise — Participants will perform supervised moderate-intensity aerobic exercise using a Meta Quest 3S virtual reality headset and game-based activities. Each session will include a 5-minute warm-up period, 30 minutes of aerobic exercise, and a 5-minute cool-down period. Sessions will be conducted twice weekly for 8 week
  • Behavioral: Treadmill-Based Aerobic Exercise — Participants will perform supervised moderate-intensity treadmill-based aerobic exercise. Each session will include a 5-minute warm-up period, 30 minutes of aerobic exercise, and a 5-minute cool-down period. Sessions will be conducted twice weekly for 8 weeks.
Study Locations (1 sites)
Bezmialem Vakif University, Istanbul, Eyupsultan Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Children and adolescents aged between 10 and 17 years * Physician-diagnosed asthma according to Global Initiative for Asthma (GINA) criteria * Stable medical treatment for asthma * Ability to participate in an aerobic exercise program * Willingness of the participant and parent/legal guardian to provide informed consent Exclusion Criteria: * Presence of orthopedic, neurological, cardiovascular, or systemic conditions limiting participation in exercise * Contraindications to virtual reality use (e.g., epilepsy, photosensitivity) * Participation in a structured exercise program within the previous month * Asthma exacerbation within the previous month * Obesity diagnosis
Conditions Asthma, Mild Asthma
Phase PHASE1
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The primary objectives of the study are: Part 1: to characterize the potency and variability of dose response on efficacy (Provocative concentration of methacholine causing at least a 20% fall in forced expiratory volume (FEV1) \[PC20\]) of salbutamol administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma. Part 2: to compare the comparative dose response on efficacy (PC20) of salbutamol when administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Drug: Salbutamol HFA-152a — A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
  • Drug: Salbutamol HFA-134a — A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
  • Drug: Placebo — A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.

Primary Outcomes

  • Part 1 & Part 2: Provocative concentration of methacholine causing at least a 20% fall in FEV1 (PC20) (Up to 11 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-08-14
Completion: 2027-02-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GlaxoSmithKline
Contact Information
Study Contact:
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Interventions
  • Drug: Salbutamol HFA-152a — A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
  • Drug: Salbutamol HFA-134a — A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
  • Drug: Placebo — A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
Study Locations (1 sites)
GSK Investigational Site, Manchester, M23 9QZ United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Male or female; females may be of childbearing potential, of nonchildbearing potential, or postmenopausal. 2. Participant must be 18 to 65 years of age inclusive, at the time of screening. 3. ≥50 kg, at the time of screening. 4. Body mass index (BMI) with 19.0-35.0 kg/m2 inclusive, at the time of screening. 4\. Documented history of asthma ≥ 6 months. 5. Receiving 1 of following asthma treatments, at a stable dose, for at least 12 weeks prior to the screening visit and is anticipated to remain stable for the duration of the study: i. Short-acting beta-agonist (SABA) only. ii. Daily maintenance low-dose inhaled corticosteroids (ICS) (defined as 100-250 μg/day fluticasone propionate or equivalent plus or minus SABA which is anticipated to remain stable for the duration of the study. iii. Daily maintenance low-dose ICS + Long-acting beta-2 agonist (LABA) therapy (low-dose ICS defined as 100-250 μg/day fluticasone propionate or equivalent as defined by GINA \[GINA, 2023\]) plus or minus SABA, which is anticipated to remain stable for the duration of the study. 6\. No severe asthma exacerbations within 6 months prior to screening and ≤1 severe exacerbation during the 12 months prior to screening. 7\. Pre-bronchodilator FEV1 ≥80% of predicted, at screening. 8. PC20 to methacholine of ≤8 mg/mL, at screening. 9. Participants should be able to withhold SABA for ≥12 hours and LABA-containing medications for ≥48 hours for the purposes of performing the spirometry and methacholine challenge at screening and during the study visits (treatment periods). 10\. A female participant is eligible to participate if she is not pregnant or breastfeeding, and Is a woman of woman of nonchildbearing potential (WONCBP) OR ii. Is a woman of child bearing potential (WOCBP) and using a contraceptive method that is highly effective. 11\. Provide signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol. 12\. Non-smokers who have not used any tobacco containing-products within 12 months prior to study start, and with a total pack year history of ≤10 pack years. Exclusion Criteria: 1. Medical Conditions 1. A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator. 2. A history of respiratory diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, cystic fibrosis, bronchiectasis, interstitial lung disease, emphysema, chronic obstructive pulmonary disease, tuberculosis, or other respiratory abnormalities other than asthma. 3. Asymptomatic gallstones. 4. History or current evidence of hematologic, neurologic, psychiatric, or other diseases that, in the opinion of the investigator, would put the participant at risk through study participation, or would affect the study analyses if the disease exacerbates during the study. 5. Recent eye surgery or any other condition in which raised intracranial pressure (caused by forceful exhalation) would be harmful. 6. Current use of cholinesterase inhibitor medication e.g., to treat myasthenia gravis. 2. Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day or participation in a clinical study within 30 days of study start, or 5 half-lives of study drug if that is longer. 3. Participants who are currently or in the last 15 days have worked nightshifts. 4. Regular alcohol consumption within 6 months prior to the study defined as: an average weekly intake of \>21 units for males or \>14 units for females. 5. A positive test result for drugs of abuse (including tetrahydrocannabinol) at screening or Day -1. 6. Use of combustible tobacco products, and non-combustible nicotine delivery systems, inclusive of cigarettes, cigars, pipes, and materials used to "vape" within 12 months prior to the start of the study.
Conditions Major Depressive Disorder, Substance Use...
Phase NA
Enrollment 620
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population. They have greater withdrawal symptoms and are more likely to relapse after quitting compared with smokers without MDD. More research is needed on how nicotine affects brain function in those with MDD. Objective: To understand how nicotine affects symptoms of depression and related brain function. Eligibility: People aged 18 to 60 years, at the time of consent, with and without MDD who do not smoke cigarettes or use other nicotine products. Design: Participants will have 2 or 3 study visits over 1 year. Participants will have 2 MRI scans no less than 4 days apart. Each scan visit will last 5 to 7 hours. At each scan, they will have urine and breath tests to screen for recent use of alcohol, nicotine, and illegal drugs. Before each scan, they will take 1 of 2 medications: nicotine or placebo. Participants will receive each medication once. They will not know which medication they are receiving at each scan. For each MRI scan, they will lie on a table that slides into a cylinder. Sometimes they will be asked to lie still. Sometimes they will complete tasks on a computer. Tasks may include identifying colors or playing games to win money. Each scan will take about 2 hours. Participants will answer questions about their thoughts, feelings, and behaviors before and after each scan. They will have a blood test after each scan.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Other: Placebo Nicotine Patch — Comparator
  • Drug: Nicotine Patch — Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner

Primary Outcomes

  • 4.Nicotine effects and symptoms of MDD (At each scan visit)
  • 3. Task and Resting State Brain (At each scan visit)
  • 2.Task-fMRI (At each scan visit)
  • 1.Resting-fMRI (At each scan visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-02
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 620 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute on Drug Abuse (NIDA)
Principal Investigators:
  • Amy C Janes, Ph.D. (PRINCIPAL_INVESTIGATOR) - National Institute on Drug Abuse (NIDA)
Contact Information
Study Contact:
NIDA IRP Screening Team
(800) 535-8254
researchstudies@nida.nih.gov
Amy C Janes, Ph.D.
(667) 312-5164
amy.janes@nih.gov
Kevin Noemer, M.A.
667-312-5225
kevin.noemer@nih.gov
National Institute on Drug Abuse
Interventions
  • Other: Placebo Nicotine Patch — Comparator
  • Drug: Nicotine Patch — Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
Study Locations (1 sites)
National Institute on Drug Abuse, Baltimore, Maryland 21224 United States
Eligibility Criteria
* INCLUSION CRITERIA: To be eligible for this study, an individual must meet all the following criteria assessed under the currently approved NIDA IRP screening protocol for the evaluation of potential research subjects (here referred to as the NIDA screening protocol). This is a protocol led by the Office of the Clinical Director (OCD) at the National Institute on Drug Abuse Intramural Research Program (NIDA IRP) to assess potential research participants eligibility for entering clinical protocols at the NIDA/IRP. Additional details can be found in the NIDA screening protocol documents. As routinely done at the NIDA IRP, the screening procedures and data collected under the NIDA screening protocol will capture information above and beyond what is necessary to determine eligibility for this protocol but allows the Investigators to assess the eligibility criteria for this protocol. In order to be eligible to participate in this study, an individual must meet all of the following criteria: All Participants: 1. Able and willing to provide written informed consent. 2. Both sexes and all ethnic origins, age between 18 and 60 at the time of consent. 3. Absence of pregnancy and breastfeeding. 4. Have a Breath Alcohol Value of 0 on all study visit days involving scanning. Participant may be rescheduled if this value is greater than 0. MDD Subjects: 1. Meet DSM-5 diagnostic criteria for current MDD at screening Clinical judgement will be used to interpret criteria. 2. Have a baseline (Hamilton Depression) HAM-D score indicative of current depression as evaluated by clinical staff. 3. Current stable serotonin modulating drug (e.g. SSRI/SNRI/serotonin modulator) treatment is allowed (no changes in the last 2 months). Specific medications will be evaluated by the MAI Remitted MDD Subjects: 1. Meet DSM-5 diagnostic criteria for remitted MDD (full remission or partial remission or past depression) Clinical judgement will be used to interpret criteria. 2. HAM-D score indicating no clinically relevant depression as evaluated by clinical staff. 3. Current stable serotonin modulating drug (e.g. SSRI/SNRI/serotonin modulator) treatment is allowed (no changes in the last 2 months). Specific medications will be evaluated by the MAI. Control Subjects (without MDD): 1. Control participants must not have current/lifetime MDD. Clinical judgement will be used to interpret criteria. 2. HAM-D score indicating no clinically-relevant depression as evaluated by clinical staff. Daily Nicotine Users (Study Arm 2): 1. Uses nicotine daily for at least six months 2. Positive urine screen for cotinine EXCLUSION CRITERIA (STUDY ARM 1): An individual who meets any of the following criteria will be excluded from participation in this study: 1. Subjects with suicidal ideation where outpatient treatment is determined unsafe. 2. Lifetime history or current diagnosis of any of the following psychiatric illnesses: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features. The MAI and/or PI/LI will reserve the right to exclude based psychiatric history not explicitly described in this criterion a. Within the control group, current use of antidepressants for psychiatric reasons will be exclusionary. The MAI reserves the right to evaluate use of antidepressants for non-psychiatric uses as appropriate for participation in the study. 3. Are cognitively impaired or have a learning disability severe enough to have required intervention throughout most or all of K-12 education. The MAI will reserve the right to evaluate if a participant s history of educational placement is likely to represent a learning disability that could significantly impact the data gathered in this study based on the severity and type of learning disability. Justification: Cognitive impairment and learning disabilities may be associated with altered brain functioning in regions recruited during laboratory task performance. 4. Heavy caffeine users (consume greater than 500 mg on a regular or daily basis. This is approximately five 8 fl oz cups of coffee). Participants will be asked to not deviate from their typical caffeine use on all scanning days. 5. May not have used any nicotine product weekly or more frequently than weekly in the past year; must never have been daily nicotine users for more than 1 month. 6. Must have an expired carbon monoxide level of less than or equal to 5 ppm and cotinine levels consistent with a non-smoker. Depending on the commercially available test used, a level equivalent to a non-smoker status will be used, ideally indicative of a urine cotinine level of around 10 ng/ml. However, given the known limitations of rapid tests to return specific quantifications of cotinine levels, if the present test is unable to quantify cotinine at this level, the lowest level of detection will be used as a cut off and MAI / PI discretion may be used to determine whether this cut off coupled with participant history and environmental factors indicates personal nicotine use versus secondhand smoke environment. 7. History of moderate or severe substance use disorder in the past 6 months (other than caffeine) 8. Current pharmacological treatment for opioid use disorder (i.e., use of methadone) 9. Current use of illegal drugs other than marijuana as measured by urine drug screen Marijuana will not be allowed in the 24 hours prior to scanning based on self-report. Study day can be rescheduled to accommodate. 10. Participants may not use anticholinergic drugs (i.e., scopolamine), dopamine enhancing drugs (i.e. methylphenidate), or other medications that may impact MRI measures (i.e. benzodiazepines) prior to any scanning visit within a timeframe that is likely to directly impact the study questions. MAI discretion regarding timeframe of allowed use will be based on half-life, pharmacology of the drug in question, and pattern of use by the participant. Scanning visit timing can be adjusted to accommodate. 11. May not use drugs that directly enhance dopamine (i.e., methylphenidate) in the week prior to any scanning visit. Scanning visit timing can be adjusted to accommodate. 12. Any past or present significant cardiovascular, cerebrovascular, or respiratory conditions, including arrhythmias, acute coronary syndrome, ischemic heart disease, or, uncontrolled hypertension. The MAI may use their clinical judgement to interpret this criterion. 13. Body mass index (BMI) lower than 18.5 kg/m\^2 14. Contraindications to MRI as determined by MRI Safety Screening form and mock scanner trial (when available). 15. Abnormal structural MRI or significant head trauma. The MAI may use their clinical judgement to interpret this criterion. 16. Current neurological illness including but not limited to frequent migraines, multiple sclerosis, movement disorder. The MAI may use their clinical judgement to interpret this criterion. 17. Lifetime history of significant seizure disorder 18. Any other serious or unstable medical illness as defined by self-report, the evaluation of vital signs or other observation that in the view of the investigators would compromise the safety of an individual during participation All data collected will be evaluated by members of the study team to decide if there is an existing medical illness that would compromise participation in this research 19. Subjects that cannot speak English. Justification: To include non-English speakers, we would have to translate the consent and other study documents and hire and train bilingual staff, which would require resources that we do not have and could not justify, given the small sample size for each experiment. Additionally, the data integrity of some of the cognitive tasks and standardized questionnaires used in this study would be compromised as they have only been validated in English.